Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective, cross-sectional, center-based chart review study that collected real-world data for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients receiving tisagenlecleucel (tisa-cel). Five centers in the United States were included for the study.
The date of the initial tisa-cel infusion was defined as the index date. A baseline period from ALL diagnosis to the index date was used to capture patient characteristics including demographics, and disease and treatment history. The study period, defined as the period from tisa-cel infusion to the end of follow-up date, i.e. the last contact date on medical charts or death, whichever was earlier, was used to capture the clinical outcomes of tisa-cel among ALL patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Tisa-cel Cohort | Patients with R/R B-cell ALL who received tisa-cel infusions between December 2020 and September 2022. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Remission Rate | Remission rate was defined as the best overall response as either complete remission (CR) or complete remission with incomplete blood count recovery (CRi) to tisa-cel. CR: <5% blasts in bone marrow based on morphologic assessment, no evidence of extramedullary disease, full recovery of peripheral blood counts (platelets > 100x10^9/L, absolute neutrophil > 1.0x10^9/L, and circulating blasts <1%), and blood transfusions independency (i.e., no transfusion or transfusion ≤7 days). CRi: <5% blasts in bone marrow, no evidence of extramedullary disease, but without full recovery of peripheral blood counts with or without blood transfusions independency. | Month 1 and Month 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients per Demographic Category | Demographic categories included:
| Baseline |
| Demgraphics: Weight |
Not provided
Inclusion criteria:
Exclusion criteria: None.
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis | East Hanover | New Jersey | 07936 | United States |
Not provided
| ID | Term |
|---|---|
| D054198 | Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Number of Patients by Disease Characteristics Category | Disease characteristics categories included:
The Karnofsky and Lansky PS are measures of functional impairment. They run from 0 to 100, where 0 is death and 100 is normal health. The Karnofsky scale is for patients aged 16 years or older. The Lansky scale is for patients younger than 16 years old. | Baseline |
| Number of Patients by Treatment Characteristics Category | Treatment characteristic categories included:
| Baseline |
| Lymphoblast Proportion in Bone Marrow Before Tisa-cel Infusion | Baseline |
| ALL Disease Duration at Tisa-cel Infusion | Baseline |
| Time From Initial Diagnosis to First Relapse | From initial diagnosis up to first tisa-cel infusion, approximately 13 years |
| Number of Patients by Time From Initial Diagnosis to First Relapse | Time intervals: <18 months, 18-36 months, and >36 months. | Baseline |
| Time From Most Recent Relapse to Initial Tisa-cel Infusion | From initial diagnosis up to first tisa-cel infusion, approximately 13 years |
| Number of Lines of Treatment Prior to Tisa-cel Infusion | Baseline |
| Time From Tisa-cel Infusion to Loss of Follow-up or Death due to Any Cause | Baseline up to approximately 3 years |
| Time From Leukapheresis to Tisa-cel Infusion | From initial diagnosis up to first tisa-cel infusion, approximately 13 years |
| Number of Doses for Initial Tisa-cel Infusion | Number of doses for initial infusion was measured among those who received multiple doses. | Baseline |
| Weight Adjusted Transduced Cell Dose Infused in Patients Who Weighed 50 kg or Less at Tisa-cel Infusion | Baseline |
| Total Cell Dose Infused in Patients Who Weighed More Than 50 kg at Tisa-cel Infusion | Baseline |
| Number of Patients by Conditions Experienced After Tisa-cel Infusion | Baseline up to approximately 3 years |
| Number of Patients by Bone Marrow Minimal Residual Disease (MRD) Status | Bone marrow MRD is a measure of the number of cancer cells remaining in the body after treatment. The number of patients overall with bone marrow MRD negative and those who achieved CR or CRi response with bone marrow MRD negative after tisa-cel infusion was measured. Bone marrow MRD negative was based on clinical assessment by the investigator. CR: <5% blasts in bone marrow based on morphologic assessment, no evidence of extramedullary disease, full recovery of peripheral blood counts (platelets > 100x10^9/L, absolute neutrophil > 1.0x10^9/L, and circulating blasts <1%), and blood transfusions independency (i.e., no transfusion or transfusion ≤7 days). CRi: <5% blasts in bone marrow, no evidence of extramedullary disease, but without full recovery of peripheral blood count with or without blood transfusions independency. | Month 1 and Month 3 |
| Duration of Remission (DOR) | DOR was defined as the time from onset of remission to relapse or death due to ALL. Relapse was defined as:
| Months 1, 6, 12, 18, 24, and 30 |
| Relapse-free Survival (RFS) | RFS was defined as the time from onset of remission to relapse or death due to any cause. Relapse was defined as:
| Months 1, 6, 12, 18, 24, and 30 |
| Event-free Survival (EFS) | EFS was defined as the time from tisa-cel infusion to the earliest of the following events: death due to any cause, relapse, treatment failure (i.e., no response), or new anticancer therapy for ALL (i.e., treatments other than tisa-cel or SCT). Relapse was defined as:
| Months 1, 6, 12, 18, 24, and 30 |
| Overall Survival (OS) | OS was defined as the time from tisa-cel infusion to the date of death due to any cause. | Months 1, 6, 12, 18, 24, and 30 |
| Number of Patients who had AlloSCT After Tisa-cel Infusion | Patient counts were categorized by:
| Up to approximately 3 years |
| Time From Tisa-cel Infusion to Subsequent AlloSCT | Baseline up to approximately 3 years |
| Number of Patients by Tisa-cel Reinfusion Received After Initial Infusion | Patient counts were categorized by:
| Up to approximately 3 years |
| Time From Initial Tisa-cel Infusion to Tisa-cel Reinfusion | Baseline up to approximately 3 years |
| Number of Patients by Type of new Anticancer Therapy (Other Than AlloSCT or Reinfusion) Received After Tisa-cel infusion | Up to approximately 3 years |
| Number of Patients by B-cell Aplasia Status After Tisa-cel Infusion | B-cell aplasia status included:
| Up to approximately 3 years |
| Time from Tisa-cel Infusion to B-cell Aplasia | Baseline up to approximately 3 years |
| Number of Patients by use of Immunoglobulin (Ig) Replacement Therapy Among Those who Experienced B-cell Aplasia | Ig replacement therapy use was categorized as follows:
| Up to approximately 3 years |
| Average Dose of Ig Replacement Therapy | Ig replacement therapy included IVIG and SCIG. | Up to approximately 3 years |
| Duration of Ig Replacement Therapy | Ig replacement therapy included IVIG and SCIG. | Up to approximately 3 years |
| Rate of Maintenance of B-cell Aplasia | Months 1, 2, 3, 6, 9, 12, 18, 24, 30 |
| Number of Patients by Hospitalizations at Initial Tisa-cel Infusion | Hospitalization categories included not hospitalized, hospitalized for Tisa-cel infusion, and subsequently admitted to intensive care unit (ICU). | Baseline |
| Length of Stay in Hospital for Initial Tisa-cel Infusion | Up to approximately 3 years |
| Number of Patients by Hospitalizations After Tisa-cel Infusion | Hospitalization categories included hospitalized, not hospitalized, and first hospitalization. | Up to approximately 3 years |
| Number of Hospitalizations After Tisa-cel Infusion | Up to approximately 3 years |
| Length of Stay in Hospital After Tisa-cel Infusion | Up to approximately 3 years |
| Time From Initial Tisa-cel Infusion to the First Hospitalization | Baseline up to approximately 3 years |
| Number of Patients by Primary Reason for the First Hospitalization | Up to approximately 3 years |
| Number of Patients by ICU Admissions After Tisa-cel Infusion | ICU admission categories included admitted to ICU, not admitted to ICU, and first ICU admission. | Up to approximately 3 years |
| Number of ICU Admissions After Tisa-cel Infusion | Up to approximately 3 years |
| Length of Stay per ICU Admission After Tisa-cel Infusion | Up to approximately 3 years |
| Number of Patients by Primary Reason for ICU Admission After Tisa-cel Infusion | Up to approximately 3 years |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |